Uses of Xorimax

1.1. What is xorimax 500mg? Xorimax 500mg has the main ingredient is Cefuroxime axetil produced in the form of blister film-coated compresses of 10 tablets, used orally. Belongs to the group of antibiotics, treatment of parasites, antivirals, antifungals.
After oral administration xorimax 500mg is absorbed from the gastrointestinal tract and rapidly hydrolyzed in the intestinal mucosa and blood to release cefuroxime into the circulation. Optimal absorption occurs when it is used immediately after a meal.
After administration of xorimax 500mg tablets, peak serum concentrations (2.9 μg/mL for the 125 mg dose, 4.4 μg/mL for the 250 mg dose, 7.7 μg/mL for the 500 mg dose) were observed. and 13.6 μg/mL for the 1000 mg dose) occurred approximately 2.4 hours after dosing when administered with food. The pharmacokinetics of xorimax 500mg are linear over the oral dose range of 125 to 1000 mg.
1.2. The distribution of xorimax 500mg Protein bound has been reported to be 33 to 50% depending on the method used. Following a single dose of xorimax 500 mg tablet 500 mg to 12 healthy volunteers, the apparent volume of distribution was 50 L (CV % = 28%). Concentrations of cefuroxime in excess of the minimum inhibition for common pathogens can be achieved in tonsils, sinus tissues, bronchial mucosa, bone, pleural fluid, synovial fluid, synovial fluid, interstitial fluid, and bile. , sputum and aqueous humor. Cefuroxime crosses the blood-brain barrier when the meninges are inflamed.
1.3. Elimination of xorimax 500mg The serum half-life is from 1 to 1.5 hours. Cefuroxime is eliminated by glomerular filtration and tubular secretion. Renal clearance is in the range of 125 to 148 mL/min/1.73 m 2

2.1. Activity against bacteria Commonly susceptible microorganisms:
Gram-positive bacteria: Staphylococcus aureus (methicillin-susceptible), coagulase-negative Staphylococcus (methicillin-susceptible), Streptococcus pyogenes, Streptococcus agalactiae Bacteria Gram-negative: Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis Spiral : Borrelia burgdorferi Acquired microorganisms:
Gram-positive bacteria: Pneumococcus Gram-negative bacteria Citrobacter freundii, intestinal gas-producing bacteria, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis Proteus spp. (except P. vulgaris), Providencia spp. Gram-positive anaerobes: Peptostreptococcus spp, Propionibacterium spp. Gram-negative anaerobes: Fusobacterium spp., Bacteroides spp. Organisms resistant to:
Gram-positive bacteria: Enterococcus faecalis, Enterococcus faecium Gram-negative bacteria: Acinetobacter spp, Campylobacter spp, Morganella morganii, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens Other: Chlamydia spp, Mycoplasma spp , Legionella spp. 2.2. Indications of xorimax 500mg For adults and children aged 13 years and over
Pharyngitis / tonsillitis xorimax 500mg tablets are indicated for the treatment of mild to moderate sore throat / tonsillitis caused by susceptible strains of Streptococcus pyogenes.
The effectiveness of xorimax 500mg in preventing rheumatic fever and treating penicillin-resistant strains of Streptococcus pyogenes has not been established in clinical trials.
Acute bacterial otitis media xorimax 500mg tablets are indicated for the treatment of pediatric patients (who can be swallowed whole) with acute bacterial otitis media caused by susceptible strains of Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pyogenes.
Acute bacterial maxillary sinusitis Xorimax 500mg tablets are indicated for the treatment of mild to moderate acute bacterial maxillary sinusitis caused by susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae (only strains that do not produce β-lactamase).
The efficacy of xorimax 500mg for sinus infections caused by Haemophilus influenzae or Moraxella catarrhalis producing β-lactamases in patients with acute bacterial maxillary sinusitis has not been determined due to insufficient numbers of isolates this in clinical trials.
Acute bacterial exacerbation of chronic bronchitis Mild to moderate acute bacterial exacerbation of chronic bronchitis caused by susceptible strains of Streptococcus pneumoniae, Haemophilus parainfluenzae (beta-lactamase negative) or Haemophilus influenzae (β-lactamase negative)
Treatment of uncomplicated skin and skin structure infections caused by susceptible strains of Saphylococcus aureus (including β-lactamase producing strains) or Streptococcus pyogenes.
Uncomplicated urinary tract infections Caused by susceptible strains of Klebsiella pneumoniae or Escherichia coli .
Uncomplicated gonorrhea xorimax 500mg tablets are indicated for the treatment of uncomplicated urethral and cervical gonorrhea caused by penicillinase-producing or non-penicillinase-producing susceptible strains of Neisseria gonorrhoeae and uncomplicated gonorrhea. rectal syndrome, in women, caused by susceptible strains of Neisseria gonorrhoeae that do not produce penicillinase.
Early Lyme disease (erythema migratory) (erythema migratory) caused by susceptible strains of Borrelia burgdorferi. To reduce the development of resistant bacteria and maintain the effectiveness of Cefuroxime Axetil and other antibacterial agents, Cefuroxime Axetil should only be used to treat or prevent infections that are proven or suspected to be caused by caused by susceptible bacteria. When information on cultures and susceptibility is available, they should be considered in the selection or adjustment of antimicrobial therapy.

2.3. Contraindications of the drug xorimax 500mg Patients with hypersensitivity to the active substance or to any of the excipients in the drug Patients with hypersensitivity to cephalosporin antibiotics. History of serious hypersensitivity (eg, anaphylaxis) to any other type of betalactam antibacterial agent (penicillins, monobactams and carbapenems). 2.4. Xorimax 500mg Adverse Reactions Hypersensitivity Reactions Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactam antibiotics because of the risk of cross-sensitization. Hypersensitivity reactions can lead to a worst-case scenario of death. In the event of a severe hypersensitivity reaction, treatment with xorimax 500mg should be discontinued immediately and adequate emergency measures initiated.
Before initiating treatment with xorimax 500 mg, the patient's history should be ascertained whether the patient is allergic to cefuroxime, cephalosporins or any other beta-lactam drug. Xorimax 500mg should be used with caution in patients with a history of non-serious hypersensitivity to other beta-lactam agents.
Jarisch-Herxheimer reaction Jarisch-Herxheimer reaction has been seen after treatment of Lyme disease with xorimax 500mg . It results directly from the bactericidal activity of cefuroxime axetil on the bacterium that causes Lyme disease, the spirochete Borrelia burgdorferi. Patients should be reassured that this is a common and often self-limiting consequence of antibiotic treatment for Lyme disease
Nonsusceptible microorganism overgrowth As with other antibiotics, the use of cefuroxime axetil can cause Candida overgrowth. Prolonged use may also lead to overgrowth of other non-susceptible organisms (eg, enterococci and Clostridium difficile), which may require discontinuation of treatment.
Pseudomembranous colitis Caused by antibacterial agents have been reported including with cefuroxime and can range in severity from mild to life-threatening. This diagnosis should be considered in patients who develop diarrhea during or after administration of xorimax 500 mg. Consideration should be given to discontinuing cefuroxime and using a Clostridium difficile-specific agent. Medicinal products that inhibit intestinal motility
Influence on diagnostic laboratory parameters The development of a positive Coombs test in association with the use of xorimax 500mg may interfere with cross-association of blood.
In the ferricyanide test where false-negative results can occur, either glucose oxidase or hexokinase methods should be used to determine blood or plasma glucose concentrations in patients receiving cefuroxime axetil.

2.5. Some other disorders such as Immune system disorders: Hives, swollen tongue. Metabolic and nutritional disorders: Anorexia. Nervous system disorders: Headache. Heart disorders: Chest pain. Respiratory disorders: Shortness of breath. Digestive disorders: Abdominal pain, abdominal cramps, flatulence, indigestion, mouth ulcers. Skin and subcutaneous tissue disorders: Rash, pruritus Renal and urinary disorders: Dysuria. Reproductive system and breast disorders: Vaginitis, vulvar itching. General Disorders and Conditions: Chills, drowsiness, thirst. 2.6. Drug interactions of xorimax 500mg Drugs that reduce stomach acidity
Drugs that reduce stomach acid can reduce the effect of xorimax 500mg compared to when taken on an empty stomach. Using drugs that reduce stomach acidity can reduce the absorption effect of xorimax 500mg when taken after meals. Take Cefuroxime Axetil at least 1 hour before or 2 hours after taking a short-acting antacid. Concomitant use with histamine-2 (H2) antagonists and proton pump inhibitors is not recommended.
Concomitant administration of probenecid with xorimax 500 mg tablets increases serum cefuroxime concentrations. Therefore, probenecid should not be used concurrently with xorimax 500mg.

Xorimax drug should be used with caution in patients with renal failure, gastrointestinal diseases, especially colitis.